References

  1. ACTIVELLA® [package insert]. Princeton, NJ: Novo Nordisk Inc; 2007.
  2. Loose-Mitchell DS, Stancel GM. Estrogens and progestins. In: Hardman JG, Limbird LE, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill; 2001:1598.
  3. Data on file. Correspondence from crude material manufacturers. Novo Nordisk Inc, Princeton, NJ.
  4. Data on file. Study report/KLIM/PD/9/USA. Novo Nordisk Inc, Princeton, NJ.
  5. Ettinger B, Pressman A, Silver P. Effect of age on reasons for initiation and discontinuation of hormone replacement therapy. Menopause. 1999;6:282-289.
  6. Johnson JV, Davidson M, Archer D, Bachmann G. Postmenopausal uterine bleeding profiles with two forms of continuous combined hormone replacement therapy. Menopause. 2002;9:16-22.
  7. Tugrul, Semih, Yildirim, Gazi, Pekin, Oya, Uslu, Husamettin, Kutlu, Tayfun, Eren, Sadiye. Comparison of two forms of continuous combined hormone replacement therapy with respect to metabolic effects. Archives of Gynecology and Obstetrics. 2007;275(5):335-339.
  8. Panay N, Ylikorkala O, Archer DF, Gut R, Lang E. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric. 2007;10:120-131.
  9. Data on file. CTR. Novo Nordisk Inc, Princeton, NJ. Trial ID: ALD-1537.
Important Safety Information